JUSH

Jushi Holdings Inc.
2 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Jushi Holdings is signaling a definitive operational pivot, delivering its first quarter of positive operating income of $1.6 million. The company demonstrated significant scale efficiencies, with gross profit margins expanding to 45%, a 500-basis-point increase year-over-year.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline shift to operating profitability, Jushi's financial foundation remains precarious. The reported operating profit of $1.6 million is a fragile figure that barely covers the company's massive interest burden, which has risen to $10.4 million per quarter.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every JUSH filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between operational efficiency and financial fragility. On one hand, Jushi has successfully navigated its most immediate debt cliffs and achieved a critical milestone in operating profitability. The expansion of gross margins to 45% and the growth in wholesale distribution indicate that the company's production capabilities are improving and scaling effectively. However, the disconnect between operating profit and net loss remains stark. The company is heavily leveraged, and its ability to service debt is currently dependent on continuous refinancing and the hope of federal regulatory shifts. The massive unrecognized tax liability remains a systemic risk that could materialize as a cash drain if the anticipated Schedule III tax relief is not fully realized or is delayed by legal challenges. Ultimately, Jushi's trajectory depends on whether the transition to adult-use in Virginia and the federal rescheduling of cannabis can offset the persistent price compression in its retail markets. Investors are now weighing a leaner, more efficient operating model against a balance sheet that remains heavily burdened by legacy debt and complex tax contingencies.

Selected Quarter

Core Takeaway

Jushi has solved its immediate liquidity crisis and improved margins, but remains a high-risk play on federal rescheduling and debt sustainability.

Investor Lens

The trade-off is between improving operational efficiency and a balance sheet that is still heavily burdened by debt and tax risk.

Watch Next

The outcome of the Virginia adult-use legislation (deadline May 23, 2026) and the impact of the Schedule III reclassification on 280E tax payments.

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.45Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 12

Gross profit margin expanded from 40% to 45% YoY.

margin expansion
80%
bullishMay 12

Refinanced near-term debt into a $160M term loan maturing in 2029.

debt restructure
70%
bearishMay 12

Net loss widened to $19.8M from $17M in the prior year period.

earnings miss
60%
bullishMay 12

DOJ reclassified medical cannabis to Schedule III, potentially easing 280E tax burdens.

regulatory action
90%
bullishMay 12

Gross profit margin expanded from 40% to 45% YoY.

margin expansion
80%
bullishMay 12

Refinanced near-term debt into a $160M term loan maturing in 2029.

debt restructure
70%
bearishMay 12

Net loss widened to $19.8M from $17M in the prior year period.

earnings miss
60%
bullishMay 12

DOJ reclassified medical cannabis to Schedule III, potentially easing 280E tax burdens.

regulatory action
90%

Filing History

10-QMay 12, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between operational efficiency and financial fragility. On one hand, Jushi has successfully navigated its most immediate debt cliffs and achieved a critical milestone in operating profitability. The expansion of gross margins to 45% and the growth in wholesale distribution indicate that the company's production capabilities are improving and scaling effectively. However, the disconnect between operating profit and net loss remains stark. The company is heavily leveraged, and its ability to service debt is currently dependent on continuous refinancing and the hope of federal regulatory shifts. The massive unrecognized tax liability remains a systemic risk that could materialize as a cash drain if the anticipated Schedule III tax relief is not fully realized or is delayed by legal challenges. Ultimately, Jushi's trajectory depends on whether the transition to adult-use in Virginia and the federal rescheduling of cannabis can offset the persistent price compression in its retail markets. Investors are now weighing a leaner, more efficient operating model against a balance sheet that remains heavily burdened by legacy debt and complex tax contingencies.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.